REGENXBIO to Host Conference Call on March 1 to Discuss Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights

Rhea-AI Summary

REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on March 1, 2022, at 4:30 p.m. ET to discuss its financial results for Q4 and full-year 2021, along with recent operational highlights. Investors can join via phone or webcast, with the recorded version available for 30 days post-call. The company leverages its proprietary NAV® Technology Platform for gene therapy, holding exclusive rights to over 100 novel AAV vectors applicable in various therapeutic areas.

Positive

• Company set to discuss Q4 and full-year 2021 financial results, indicating transparency with investors.
• NAV® Technology Platform has exclusive rights to over 100 novel AAV vectors, suggesting a strong pipeline potential.

Negative

• None.

ROCKVILLE, Md., Feb. 22, 2022 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Tuesday, March 1, 2022, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2021, and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international) and enter the passcode 7635958. To access a live or recorded webcast of the call, please visit the Investors section of the REGENXBIO website at www.regenxbio.com. The recorded webcast will be available for approximately 30 days following the call.

About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

Contacts:
Dana Cormack
Corporate Communications
dcormack@regenxbio.com 

Investors:
Chris Brinzey
ICR Westwicke
339-970-2843
chris.brinzey@westwicke.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/regenxbio-to-host-conference-call-on-march-1-to-discuss-fourth-quarter-and-full-year-2021-financial-results-and-recent-operational-highlights-301487848.html

SOURCE REGENXBIO Inc.

FAQ

When is the REGENXBIO earnings call?

The REGENXBIO earnings call is scheduled for March 1, 2022, at 4:30 p.m. ET.

What financial results will REGENXBIO discuss in its upcoming call?

REGENXBIO will discuss its financial results for the fourth quarter and full-year 2021.

How can I access the REGENXBIO conference call?

You can access the call by phone at (855) 422-8964 (domestic) or (210) 229-8819 (international) and entering passcode 7635958, or through a live webcast on their website.

What is the significance of REGENXBIO's NAV Technology Platform?

REGENXBIO's NAV Technology Platform is critical for gene therapy development, holding exclusive rights to over 100 novel AAV vectors, enhancing its therapeutic pipeline.